05:57 PM EST, 12/09/2024 (MT Newswires) -- Gilead Sciences' ( GILD ) Kite unit said Monday that long-term data from four analyses underpin the "durable efficacy and survival benefits" of its tecartus in people with relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia.

The company presented the data at the 66th American Society of Hematology Annual Meeting and Exposition.

A primary analysis of cohort 3 in a phase 2 ZUMA study indicates an overall response rate of 91% and a complete response rate of 73% in Bruton tyrosine kinase inhibitor-naive patients, Gilead said.

"Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 showed that 39% of patients with R/R MCL were still alive after five years, underscoring tecartus as the only CAR T to have five-year follow-up data in this patient population," the company added.

Citing "real-world evidence outcomes" in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, Kite said tecartus also demonstrated a "high effectiveness and consistent safety profile in a broader patient population than the pivotal ZUMA-3 study."